129 128
121. (New) The method of claim ~~120~~, wherein the biomolecule is a fusion protein.

FJ cont
130 129
122. (New) The method of claim ~~121~~ wherein the cell is a mammalian cell.

131 129
123. (New) The method of claim ~~121~~ wherein the cell is a pathogen cell.

REMARKS

Claims 1, 2, 6-12, 23-27, 50-54 and 56-58 have been canceled. Claims 59-123 have been added. Below are some of the locations in the specification where support for new Claims 59-123 can be found.

Claim	Support
59	original claim 7; for "protein target components" see page 13, lines 3-9, page 19, lines 2-7, page 20, lines 4-5, page 22, lines 22-27, page 36, lines 8-10 and page 38, lines 4-7
60	original claim 8
61	original claim 8
62	page 10, lines 6-7
63	page 10, lines 6-7
64	regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S. aureus* methionyl tRNA synthetase as target cell components.
65	page 11, line 6
66	The Examples illustrate fusion proteins as biomolecules binding to target enzymes.
67	original claim 10
68	original claim 9
69	page 10, lines 6-11
70	regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S.*

aureus methionyl tRNA synthetase as target cell components.

71 page 11, line 6

72 page 11, line 6

73 The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

74 original claim 10

75 original claim 9

76 original claims 1 and 3

77 original claim 6

78 original claims 1, 4 and 6

79 original claims 1 and 4; page 10, lines 6-7

80 original claims 1 and 4; page 10, lines 6-7

81 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S. aureus* methionyl tRNA synthetase as target cell components.

82 page 11, line 6

83 original claims 1 and 4; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

84 original claims 1 and 4; page 10, lines 6-11

85 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate *E coli* prolyl tRNA synthetase and *S. aureus* methionyl tRNA synthetase as target cell components.

86 page 11, line 6

87 page 11, line 6

88 The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

89 original claim 7; page 11, line 6

90 original claim 8

91 original claims 7 and 8; page 11, line 6

92 page 5, lines 9-19

93 original claim 7; page 11, line 6; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

94 page 10, lines 6-7

95 page 10, lines 6-7

96 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S. aureus* methionyl tRNA synthetase as target cell components.

97 original claim 10

98 original claim 9

99 page 5, lines 9-19

100 original claim 8; page 5, lines 9-19; page 10, lines 6-11

101 original claim 10

102 original claim 9

103 original claims 1, 3 and 4; page 11, line 6

104 original claims 8 and 9

105 original claims 1, 3, 4 and 8; page 11, line 6

106 page 5, lines 9-19

107 original claims 1, 3, and 4; page 11, line 6; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

108 page 10, lines 6-7

109 page 10, lines 6-7

110 regarding target enzymes, see page 15, lines 8-10, page 15, lines 20-23, and page 28, lines 10-13. The Examples illustrate *E. coli* prolyl tRNA synthetase and *S. aureus* methionyl tRNA synthetase as target cell components.

111 original claim 23

112 original claim 23

113 original claim 23

114 original claim 23; page 11, line 6

115 original claim 23; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

116	original claims 10 and 23
117	original claims 9 and 23
118	original claims 23 and 25
119	original claims 23 and 25
120	original claims 23 and 25; page 11, line 6
121	original claims 23 and 25; page 11, line 6; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.
122	original claims 10, 23 and 25; page 11, line 6; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.
123	original claims 9, 23 and 25; page 11, line 6; The Examples illustrate fusion proteins as biomolecules binding to target enzymes.

Cancellation of pending claims and redrafting of the claims as newly added claims 59-123 has been done to simplify and make more clear the language of the claims. The newly added claims address the concerns in regard to the Bostian *et al.* (WO 96/40979) reference raised by the Examiner in the Office Action of May 23, 2002, and in a telephonic conference with the undersigned attorney on October 18, 2002. In the newly added claims, the biomolecule interacts with the target component by binding to it. The language of the claims does not encompass RNA-RNA or RNA-DNA interactions as biomolecule and target component interactions.

CONCLUSION

The Examiner is respectfully requested to consider the above amendments and remarks. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Carol A. Egner

Carol A. Egner
Registration No. 38,866
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133
Dated: December 12, 2002